Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
INTERVIEW
I’ve Done Everything I Can in 11 Years, Says Outgoing PMDA Chief
Tatsuya Kondo, chief executive of the Pharmaceuticals and Medical Devices Agency (PMDA), is hitting the exit at the end of the month after 11 years at the helm. What was behind his decision to leave? How does he view his…
To read the full story
Related Article
- Ex-PMDA Chief Kondo, Credited with Eliminating Japan’s Drug Lag, Dies at 79
September 30, 2021
- PMDA Chief Kondo to Step Down after 11 Years in Charge
March 25, 2019
INTERVIEW
- Interview: Mathematician Changing the Future of Drug Discovery (FRONTEO CTO)
March 25, 2025
- From Treatment to Prevention, Top Expert on AD Research, Aducanumab and Its Implications - 2
February 8, 2021
- Alzheimer’s Treatment at Crossroads? Top Expert on AD Research, Aducanumab and Its Implications - 1
February 2, 2021
- Improper Materials Apparently Decreased after Promotion Guidelines Introduced: Pharmacist
February 10, 2020
- “Excessive Self-Restraint” of Promotion Activities by Drug Makers Hindering Drugs’ Lifecycle Management: Physician
January 28, 2020
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…